miR-342-5p/AnkG Pathway in Early AD Synaptic Dysfunction
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age50+
SponsorThe Fourth Affiliated Hospital of Zhejiang University School of Medicine
About this trial
Alzheimer's disease is the most common memory loss disease among the elderly. This disease affects the patient's memory, language, attention, and behavioral abilities. Current research has found that in the early stages of the disease, synaptic connections between brain nerve cells become abnormal, but the specific cause is still unclear. Investigators' previous research discovered that in the brains of diseased mice, certain special substances (the miR 342 5p/AnkG-mediated pathway) might be related to this abnormality, and these substances can be detected in both blood and cerebrospinal fluid. Therefore, investigators want to further explore the specific mechanisms of abnormal nerve cell connections, seek biomarkers for early detection of the disease, and provide new ideas for early diagnosis in the future.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Meet the diagnostic criteria for "probable AD dementia" established by the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA)
MMSE score between 0-23 points, Clinical Dementia Rating (CDR) score ≥0.5 points, Hachinski Ischemic Score <4 points
Brain MRI showing bilateral temporal lobe and hippocampal atrophy
Age ≥50 years
Disqualifiers
Dementia or cognitive impairment caused by other diseases
History of substance abuse
Progressive primary aphasia
Previous traumatic brain injury
Trial design
Design model
Parallel
Treatments tested in this trial
Collect peripheral blood, and if the patient consents, also collect cerebrospinal fluid.
Other interventionCollect peripheral blood, and if the patient consents, also collect cerebrospinal fluid.
Treatment groups
40 Participants
are divided into 2 treatment groupsGroup A: AD GroupExperimental treatment 1 intervention
Group B: Healthy control groupOther 1 intervention
Trial outcomes
Primary outcomes
1
Correlation between miR-342-5p/AnkG Pathway and Synaptic Proteins
Quantitative Reverse Transcription-Polymerase Chain Reaction (QT-PCR) detection of microRNA-342-5p (miR-342-5p), Cytometric Bead Array (CBA) method detection of Ankyrin-G (AnkG), and Electrochemiluminescence (ECL) technology detection of neurogranin. Then analyze the correlation between miR-342-5p/AnkG and the synaptic protein neurogranin
Time frame
Within 12 weeks after enrollmentSecondary outcomes
1
The correlation between miR-342-5p/AnkG pathway and cognitive function and brain atrophy
miR-342-5p was detected by qRT-PCR, AnkG was measured by CBA method, cognitive function was evaluated using neuropsychological scales, and hippocampal atrophy was assessed by structural MRI.Then analyze the correlation between miR-342-5p/AnkG and cognitive function and hippocampal atrophy
Time frame
Within 12 weeks after enrollmentSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov